Calamos Advisors LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$1,044,343
-15.0%
18,354
-40.9%
0.01%
-16.7%
Q3 2022$1,228,000
-72.3%
31,051
-69.2%
0.01%
-68.4%
Q2 2022$4,432,000
+65.2%
100,724
+56.5%
0.02%
+26.7%
Q1 2021$2,683,000
-46.6%
64,359
-45.3%
0.02%
-48.3%
Q4 2020$5,028,000
+99.0%
117,716
+22.4%
0.03%
+81.2%
Q3 2020$2,527,000
+101.7%
96,171
+105.9%
0.02%
+77.8%
Q2 2020$1,253,00046,7030.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders